- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears RadNet's Updated AI Software for Prostate MRI
An update to Quantib Prostate 2.1, Quantib Prostate 3.0 reportedly facilitates workflow advances and offers a variety of tools, ranging from artificial intelligence (AI)-based segmentation to PI-RADS scoring support, to help improve interpretation of prostate magnetic resonance imaging (MRI).
The Food and Drug Administration (FDA) has granted 510(k) clearance to Quantib Prostate 3.0 (RadNet), an artificial intelligence (AI)-based software that may bolster radiology workflow and interpretation of prostate magnetic resonance imaging (MRI).
Key features for Quantib Prostate 3.0, an update to Quantib Prostate 2.1 software, include an improved algorithm for prostate and subregion segmentation and automated lesion drawing on the PI-RADS sector map, according to RadNet.
The company adds that other benefits for enhancing the quality and speed of prostate MRI reporting include PSA (prostate-specific antigen) density calculation, one-click segmentation of lesion candidates, and precise registration and movement correction.
“The (clearance) of Quantib Prostate 3.0 represents another step forward in advancing prostate cancer care by bringing the latest in AI technology to MRI interpretation,” noted Gregory Sorenson, M.D., the president of RadNet’s AI Division. “With the increasing recognition of the important role MRI plays in prostate cancer diagnosis, we believe physicians will value the power that this software puts in their hands.”
(Editor’s note: For related content, see “Emerging Prostate and Brain MRI AI Platform Gets FDA Nod” and “Can Explainable AI Enhance Diagnosis and PI-RADS Classification of Prostate Cancer on MRI?”)
Are Prostate Biopsies Necessary in Patients with Negative or Equivocal MRIs and Low PSA Density?
April 2nd 2024Up to 48 percent of unnecessary prostate biopsies could be eliminated by limiting biopsy to patients with PI-RADS 4 and higher MRI assessments and a prostate-specific antigen density level below 0.15 ng/mL2, according to a new meta-analysis.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.
